Who makes Rescue papaverine, as needed?

Rescue papaverine, as needed is developed by The University of Texas Health Science Center, Houston.

What development phase is Rescue papaverine, as needed in?

Rescue papaverine, as needed is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Rescue papaverine, as needed

The University of Texas Health Science Center, Houston · FDA-approved active Small molecule Quality 0/100

Rescue papaverine, marketed by The University of Texas Health Science Center, Houston, is a drug used as needed for specific conditions, though its primary indication is not specified. A key strength is the protection provided by a key composition patent, which expires in 2028. The primary risk is the lack of detailed revenue data and key trial results, which may limit strategic planning and market positioning.

At a glance

Generic name	Rescue papaverine, as needed
Sponsor	The University of Texas Health Science Center, Houston
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Papaverine vs Heparin for Peripheral Arterial Catheter Patency in Pediatric Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rescue papaverine, as needed CI brief — competitive landscape report
Rescue papaverine, as needed updates RSS · CI watch RSS
The University of Texas Health Science Center, Houston portfolio CI